99 related articles for article (PubMed ID: 28873000)
1. Immunohistochemical Analysis Using Antipodocalyxin Monoclonal Antibody PcMab-47 Demonstrates Podocalyxin Expression in Oral Squamous Cell Carcinomas.
Itai S; Yamada S; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):220-223. PubMed ID: 28873000
[TBL] [Abstract][Full Text] [Related]
2. PcMab-47: Novel Antihuman Podocalyxin Monoclonal Antibody for Immunohistochemistry.
Ogasawara S; Kaneko MK; Yamada S; Honma R; Nakamura T; Saidoh N; Yanaka M; Yoshida K; Fujii Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):50-56. PubMed ID: 28384052
[TBL] [Abstract][Full Text] [Related]
3. 47-mG
Kaneko MK; Itai S; Yamada S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Jun; 37(3):158-161. PubMed ID: 29630446
[TBL] [Abstract][Full Text] [Related]
4. Anti-Podocalyxin Monoclonal Antibody 47-mG
Yamada S; Itai S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):91-94. PubMed ID: 29649375
[TBL] [Abstract][Full Text] [Related]
5. Determination of critical epitope of PcMab-47 against human podocalyxin.
Itai S; Yamada S; Kaneko MK; Kato Y
Biochem Biophys Rep; 2018 Jul; 14():78-82. PubMed ID: 29872738
[TBL] [Abstract][Full Text] [Related]
6. A Cancer-Specific Monoclonal Antibody against Podocalyxin Exerted Antitumor Activities in Pancreatic Cancer Xenografts.
Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203331
[TBL] [Abstract][Full Text] [Related]
7. Epitope Mapping of a Cancer-Specific Anti-Podocalyxin Monoclonal Antibody (PcMab-60) Using Enzyme-Linked Immunosorbent Assay and Surface Plasmon Resonance.
Asano T; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Oct; 40(5):227-232. PubMed ID: 34678093
[TBL] [Abstract][Full Text] [Related]
8. Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.
Kaneko MK; Kunita A; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Ogasawara S; Ohishi T; Abe S; Itai S; Harada H; Kawada M; Nishioka Y; Fukayama M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):157-162. PubMed ID: 28665782
[TBL] [Abstract][Full Text] [Related]
9. Anti-podocalyxin antibody exerts antitumor effects via antibody-dependent cellular cytotoxicity in mouse xenograft models of oral squamous cell carcinoma.
Itai S; Ohishi T; Kaneko MK; Yamada S; Abe S; Nakamura T; Yanaka M; Chang YW; Ohba SI; Nishioka Y; Kawada M; Harada H; Kato Y
Oncotarget; 2018 Apr; 9(32):22480-22497. PubMed ID: 29854293
[TBL] [Abstract][Full Text] [Related]
10. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
Kaneko MK; Ohishi T; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
[TBL] [Abstract][Full Text] [Related]
11. Establishment of EMab-134, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Detecting Squamous Cell Carcinoma Cells of the Oral Cavity.
Itai S; Yamada S; Kaneko MK; Chang YW; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Dec; 36(6):272-281. PubMed ID: 29090976
[TBL] [Abstract][Full Text] [Related]
12. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
13. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy.
Snyder KA; Hughes MR; Hedberg B; Brandon J; Hernaez DC; Bergqvist P; Cruz F; Po K; Graves ML; Turvey ME; Nielsen JS; Wilkins JA; McColl SR; Babcook JS; Roskelley CD; McNagny KM
Breast Cancer Res; 2015 Mar; 17(1):46. PubMed ID: 25887862
[TBL] [Abstract][Full Text] [Related]
14. Podocalyxin is crucial for the growth of oral squamous cell carcinoma cell line HSC-2.
Itai S; Yamada S; Kaneko MK; Sano M; Nakamura T; Yanaka M; Handa S; Hisamatsu K; Nakamura Y; Furusawa Y; Fukui M; Ohishi T; Kawada M; Harada H; Kato Y
Biochem Biophys Rep; 2018 Sep; 15():93-96. PubMed ID: 30105309
[TBL] [Abstract][Full Text] [Related]
15. PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin.
Canals Hernaez D; Hughes MR; Dean P; Bergqvist P; Samudio I; Blixt O; Wiedemeyer K; Li Y; Bond C; Cruz E; Köbel M; Gilks B; Roskelley CD; McNagny KM
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243933
[TBL] [Abstract][Full Text] [Related]
16. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma.
Lin CW; Sun MS; Wu HC
Int J Oncol; 2014 Aug; 45(2):710-8. PubMed ID: 24821609
[TBL] [Abstract][Full Text] [Related]
17. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin expression in squamous cell carcinoma of the lung and oral cavity: an immunohistochemical study with possible clinical relevance.
Hamakawa H; Bao Y; Takarada M; Fukuzumi M; Tanioka H
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1998 Apr; 85(4):438-43. PubMed ID: 9574953
[TBL] [Abstract][Full Text] [Related]
19. PMab-38 Recognizes Canine Podoplanin of Squamous Cell Carcinomas.
Kaneko MK; Honma R; Ogasawara S; Fujii Y; Nakamura T; Saidoh N; Takagi M; Kagawa Y; Konnai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Oct; 35(5):263-266. PubMed ID: 27788030
[TBL] [Abstract][Full Text] [Related]
20. Development of EMab-51, a Sensitive and Specific Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Flow Cytometry, Western Blot, and Immunohistochemistry.
Itai S; Kaneko MK; Fujii Y; Yamada S; Nakamura T; Yanaka M; Saidoh N; Handa S; Chang YW; Suzuki H; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Oct; 36(5):214-219. PubMed ID: 28891752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
